Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 36Neoplasm Metastasis 12Neoplasms 10Colorectal Neoplasms 5Thyroid Neoplasms 4Thyroid Cancer, Papillary 4Multiple Myeloma 4Leukemia, Hairy Cell 4Hematologic Neoplasms 4Skin Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Thyroid Carcinoma, Anaplastic 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Brain Neoplasms 2Thyroid cancer, follicular 1Thrombocytosis 1Sarcoma, Clear Cell 1Sarcoma 1Relapsed Pediatric Solid Tumor 1Rare Tumour 1Rare Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pazopanib 2Ifosfamide 2Etoposide 2Carboplatin 2vandetanib 1ruxolitinib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Relapsed Pediatric Solid Tumor × Vemurafenib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡